GIP Receptor Antagonist Studies in Humans

NCT02747472 ↗

Completed 10 enrolled University Hospital, Gentofte, Copenhagen University of Copenhagen · collab

RandomizedCrossoverTriple-blindBasic science

Summary

Antagonizing GIP effects during hyperglycaemia in healthy subjects and measurements of insulin secretion.

Timeline

Start: 2016-04
Primary completion: 2016-07
Completion: 2016-07

Outcome

Met primary endpoint

paper GIP-induced insulin secretion was reduced by 82% (p < 0.0001) during co-infusion with GIP(3-30)NH2, and the need for glucose was reduced to placebo levels. PMID 28948296 ↗

Publications

Gasbjerg LS, Christensen MB, Hartmann B, Lanng AR, Sparre-Ulrich AH, Gabe MBN, Dela F, Vilsboll T, Holst JJ, Rosenkilde MM, Knop FK. GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia. 2018 Feb;61(2):413-423. doi: 10.1007/s00125-017-4447-4. Epub 2017 Sep 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GIP(1-42)	Unknown	1.5 unknown	Intravenous
Subject	GIP-A	Peptide	800 unknown	—